(Reuters) – Oculis Holding said on Monday its drug to treat a type of eye disorder met its main goal in a late-stage study, sending its shares up about 15% in premarket trading.
The company is testing the drug, OCS-01, to treat diabetic macular edema which is a leading cause of blindness in patients with diabetes.
Patients treated with the drug showed strong visual gain compared to a vehicle, which is similar to a placebo, Oculis said.
OCS-01 was well-tolerated in the study and the company plans to begin a second part of its late-stage study later this year.
(Reporting by Bhanvi Satija and Pratik Jain in Bengaluru; Editing by Janane Venkatraman and Nivedita Bhattacharjee)
Source: Read Full Article
